Literature DB >> 11103825

Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.

S Y Sun1, P Yue, W K Hong, R Lotan.   

Abstract

The synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) induces apoptosis in a variety of cancer cells. Recently, we demonstrated that CD437 induces apoptosis in human non-small cell lung cancer (NSCLC) cells expressing wild-type p53 by increasing the level of the death domain-containing cell surface receptor Killer/DR5. In the present study, we investigated whether CD437 induced the expression of Fas (CD95/APO-1), a cell surface protein belonging to the tumor necrosis factor receptor superfamily, which induces apoptosis upon interaction with Fas ligand (FasL) or agonistic antibodies. We found that CD437 increased the level of Fas mRNA in a time- and concentration-dependent manner in NSCLC H460 cells. The increased Fas expression was also identified at the protein level. CD437 induced Fas expression in three NSCLC cell lines with wild-type p53 but not in six NSCLC cell lines containing mutant p53. Moreover, enhanced degradation of wild-type p53 protein in NSCLC cells expressing human papillomavirus-16 E6 oncoprotein blocked CD437-induced Fas expression. These results implicate the involvement of wild-type p53 in CD437-induced Fas expression in human NSCLC cells. CD437 did not change Fas mRNA stability, and actinomycin D abolished CD437-induced expression of Fas mRNA, suggesting that CD437 induces Fas expression at the transcriptional level. The combination of CD437 and FasL or CD437 and agonistic anti-Fas antibody caused synergistic induction of apoptosis. Furthermore, CD437 augmented Fas/ FasL-induced apoptosis in cell lines with wild-type p53 but not in cell lines having mutant p53, indicating that a p53-dependent mechanism is also involved in this effect. Taken together, these results demonstrate that increased Fas expression may play an important role in CD437-induced, p53-dependent apoptosis in human NSCLC cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103825

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models.

Authors:  Angela Maria Di Francesco; Paolo Ubezio; Anna Rita Torella; Daniela Meco; Filomena Pierri; Giuseppe Barone; Gabriella Cusano; Claudio Pisano; Maurizio D'Incalci; Riccardo Riccardi
Journal:  Invest New Drugs       Date:  2011-06-03       Impact factor: 3.850

2.  Gallium compound GaQ(3) -induced Ca(2+) signalling triggers p53-dependent and -independent apoptosis in cancer cells.

Authors:  Rajan Gogna; Esha Madan; Bernhard Keppler; Uttam Pati
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles.

Authors:  Santiago Pérez-Rodríguez; Maria A Ortiz; Raquel Pereira; Fátima Rodríguez-Barrios; Angel R de Lera; F Javier Piedrafita
Journal:  Eur J Med Chem       Date:  2009-01-20       Impact factor: 6.514

Review 4.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

5.  Asperfuranone from Aspergillus nidulans inhibits proliferation of human non-small cell lung cancer A549 cells via blocking cell cycle progression and inducing apoptosis.

Authors:  Clay C C Wang; Yi-Ming Chiang; Mike B Praseuth; Po-Lin Kuo; Hsin-Lin Liang; Ya-Ling Hsu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-02-09       Impact factor: 4.080

6.  Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors.

Authors:  Nunghathai Sawasdee; Methichit Wattanapanitch; Nontaphat Thongsin; Nattaporn Phanthaphol; Chutipa Chiawpanit; Chanitra Thuwajit; Pa-Thai Yenchitsomanus; Aussara Panya
Journal:  Int J Mol Med       Date:  2022-02-04       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.